At a glance
- Originator Pharmacia Corporation
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 07 Jul 1998 No-Development-Reported for Atherosclerosis (Unknown route)
- 07 Jul 1998 No-Development-Reported for Hyperlipidaemia (Unknown route)